0001214659-24-004302.txt : 20240311 0001214659-24-004302.hdr.sgml : 20240311 20240311103453 ACCESSION NUMBER: 0001214659-24-004302 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230310 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wargacki Stephen CENTRAL INDEX KEY: 0001960165 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38599 FILM NUMBER: 24736919 MAIL ADDRESS: STREET 1: C/O AQUESTIVE THERAPEUTICS, INC. STREET 2: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc. CENTRAL INDEX KEY: 0001398733 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208623253 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-941-1900 MAIL ADDRESS: STREET 1: 30 TECHNOLOGY DRIVE CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: MonoSol Rx, Inc. DATE OF NAME CHANGE: 20070507 4 1 marketforms-64695.xml PRIMARY DOCUMENT X0508 4 2023-03-10 0001398733 Aquestive Therapeutics, Inc. AQST 0001960165 Wargacki Stephen C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE WARREN NJ 07059 false true false false SVP, Research & Development 0 Common Stock 2023-03-10 4 F false 1981 .7937 D 158419 D Common Stock 2024-03-07 4 A false 112500 0 A 270919 D Non-Qualified Stock Option (right to buy) 5.68 2024-03-07 4 A false 56250 0 A 2034-03-07 Common Stock 56250 56250 D Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. The original Form 3, filed on 1/1/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares vested that occurred on 3/10/22 as a total of 4,663 shares vested and owned when in fact 3,107 shares of the Issuer's common stock were owned, net of taxes withheld. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 1,556 shares reflecting share withheld for the payment of taxes. The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. /s/ Lori Braender, as Attorney-In-Fact 2024-03-11